Choroidal neovascularisation complicating geographic atrophy in age-related macular degeneration.
OBJECTIVE
To investigate the morphological and functional outcomes after intravitreal ranibizumab injections for choroidal neovascularisation (CNV) complicating geographic atrophy (GA).


METHODS
Retrospective, interventional, consecutive case series.


METHODS
We reviewed the charts of all consecutive patients with GA due to age-related macular degeneration (AMD), who received intravitreal ranibizumab injections for the development of CNV at least 24 months earlier.


RESULTS
21 treatment-naive eyes of 21 consecutive patients (4 men, 17 women, mean age 86.9 ± 1.6 years) were included. In 95.2% of eyes a type 2 CNV was present, extrafoveal in 42.8% of cases. After a mean of 5.0 ± 0.87 (range 1-20) intravitreal ranibizumab injections, best-corrected visual acuity (BCVA) significantly worsened at the 24-month follow-up visit (0.73 ± 0.05 vs 0.88 ± 0.08 logMAR, respectively; p=0.01). A significant reduction of intraretinal cystic lesions, subretinal fluid and pigment epithelium detachment (p<0.001) and a significant increase of GA area (p=0.003) were present at last visit.


CONCLUSIONS
Ranibizumab treatment of GA-associated CNVs provides no BCVA improvement at 24 months follow-up despite an anatomic response of CNV. Low effectiveness of ranibizumab in these cases is likely due to GA progression.
Department of Ophthalmology, University Paris Est Creteil, Centre Hospitalier Intercommunal de Creteil, 40 Avenue de Verdun, Creteil 94000, France. giuseppe.querques@hotmail.it
Giuseppe
G
Querques
Nathalie
N
Massamba
Florence
F
Coscas
Raimondo
R
Forte
Eric H
EH
Souied
D000368:Aged; D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology*; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005654:Fundus Oculi; D057092:Geographic Atrophy / Q000150:complications* / Q000175:diagnosis; D006801:Humans; D058449:Intravitreal Injections; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D000069579:Ranibizumab; D012189:Retrospective Studies; D014792:Visual Acuity
D061067:Antibodies, Monoclonal, Humanized; D000069579:Ranibizumab